Mepafuran

Quick links to important sections

Mepafuran

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mepafuran

Property Description
Active ingredient Nitrofurantoin
Pharmacological class Antibacterial agent / Nitrofuran class
Origin Synthetic organic compound
Form Oral capsule, Oral tablet, Oral suspension
Route of administration Oral
Product type Single-ingredient, Prescription-only

Mepafuran is a prescription-only antibacterial agent that provides targeted anti-infective management. The medication's identity is defined by its sole active ingredient, Nitrofurantoin, which is a highly effective synthetic compound for combating susceptible bacterial populations. Nitrofurantoin is classified as an antibacterial agent and is primarily used as a urinary anti-infective. This use scenario is clinically recognized for managing bacterial presence in the lower urinary system.


Classification and Identity of the Active Ingredient

Mepafuran belongs to the distinct Nitrofuran class, a pharmacological class that utilizes a unique chemical structure to exert its effect, distinguishing it from common antibacterial groups like penicillins or cephalosporins. The active ingredient, Nitrofurantoin, is a synthetic organic compound, confirming it is chemically engineered as a Nitrofuran derivative. This compound is typically rapidly absorbed and excreted.


Origin, Composition, and Available Forms

The Mepafuran preparation is a single-ingredient product designed for oral administration, exclusively containing Nitrofurantoin along with necessary pharmaceutical excipients. The dosage forms, including the oral capsule and oral tablet, often utilize specialized structures, such as the macrocrystalline form. The benefit of this controlled release is optimized drug delivery, which serves to improve patient absorption and tolerance profiles. This differentiation in formulation means Mepafuran may be specifically positioned for adults requiring the convenience of a sustained-release format.


General Purpose of this Urinary Tract Anti-infective

The general purpose of Mepafuran is to provide focused anti-infective management by acting as a bactericidal agent. This function is achieved because the medicine is specifically engineered to maintain a low plasma concentration in the bloodstream while attaining a high urinary concentration. This unique characteristic functionally classifies Mepafuran as a highly targeted urinary tract anti-infective, defining its primary therapeutic benefit by concentrating the antibacterial agent exactly in the anatomical location where the pathogens reside.

Regulatory References

  1. Nitrofurantoin: MedlinePlus Drug Information

What side effects are possible with Mepafuran?

Possible Side Effects and Safety Information

The safety profile of Mepafuran is documented in official government regulatory sources, detailing the potential for adverse reactions across several body systems.

Adverse Reactions and Frequencies

Adverse reactions are classified by frequency and system-organ class:

  • Common Reactions: Nausea, vomiting, loss of appetite (anorexia), and diarrhea are frequently reported side effects.
  • System-Organ Classes Involved: Reactions affect the Gastrointestinal, Respiratory, Hepatobiliary, Nervous, Blood and Lymphatic, and Immune systems.

Serious and Clinically Significant Risks

Regulatory documents emphasize the potential for serious, sometimes irreversible, and even fatal organ toxicities:

  • Organ Toxicity: Severe reactions have been reported involving the lungs (acute, subacute, and chronic pulmonary reactions, including pulmonary fibrosis), the liver (hepatitis, including chronic active hepatitis), and the nervous system (peripheral neuropathy). Fatalities have been associated with chronic active hepatitis and peripheral neuropathy.
  • Hypersensitivity: Rare but serious immune-mediated reactions include anaphylaxis, lupus-like syndrome, and DRESS syndrome.

Safety Restrictions and Limitations

Official safety documents define specific patient populations and conditions for which Mepafuran is restricted or contraindicated:

  • Renal Function: The medicine is contraindicated in patients with severely impaired kidney function, specifically a creatinine clearance of less than 60 mL/minute.
  • Pregnancy and Neonates: It is contraindicated in late-stage pregnancy (at term, 38–42 weeks gestation) and in neonates under one month of age, due to the risk of hemolytic anemia.
  • Exposure-Related Risk: The risk of serious chronic reactions, particularly chronic pulmonary and liver damage, is explicitly noted as being higher with long-term therapy (generally six months or longer). If signs of organ toxicity or severe hypersensitivity occur, discontinuation is mandated by official safety instructions.

Overdose and Emergency Response

Overdose and when to seek help

Suspected Mepafuran overdose requires immediate emergency medical attention. Regulator guidance mandates that users contact a Poison Control Center immediately or seek emergency medical care. If the individual has collapsed, experienced a seizure, or has trouble breathing, emergency services must be called.

Overdose Findings Regulatory Statements
Documented Manifestation Vomiting is the primary documented acute manifestation reported in overdose scenarios.
Serious Risks Overdose exposure carries a risk of severe systemic toxicity, including damage to the Hepatic and Pulmonary systems and Peripheral Neuropathy. These outcomes may be life-threatening or irreversible.
Population Risk The risk of toxicity is significantly enhanced in individuals with impaired renal function (creatinine clearance less than 60 mL per minute), as official regulatory documents confirm that reduced drug excretion elevates systemic concentration.

The official management approach for Mepafuran overdose focuses entirely on symptomatic and supportive treatment, as no specific antidote is known. Officially described supportive measures include increasing fluid intake to promote drug elimination through the urine. Due to the severe nature of the potential toxicities, hospital monitoring may be required for continuous observation and care. Dialysis is a documented procedure reserved for extreme cases where aggressive removal of the drug from circulation is necessary.

Therapeutic Uses of Mepafuran

The primary therapeutic role of Mepafuran may assist with addressing symptomatic discomfort associated with lower urinary infections.

Mepafuran is commonly used in the symptomatic management of acute uncomplicated urinary tract infections (UTIs). This makes it relevant in conditions characterized by periods of heightened symptoms associated with inflammation. It is applied within clinical settings that involve acute or disruptive symptom patterns, and is used when additional symptomatic support is needed.


Management of Acute Lower Urinary Symptoms

Mepafuran is generally used to help with conditions characterized by periods of heightened symptoms associated with inflammatory or irritative states. It helps address symptom clusters that create noticeable physiological strain, including painful or burning urination (dysuria), a sudden need to urinate, and increased frequency of voiding. The primary benefit is that it supports patients during episodes of heightened discomfort, which helps maintain a sense of stability when symptoms are more noticeable. It is commonly used across conditions presenting with acute episodes, including those associated with cystitis.


Prophylactic Support Against Infection Recurrence

Mepafuran is considered relevant in contexts involving recurrent or episodic manifestations of urinary tract discomfort. It is applied across domains where additional symptomatic support is needed to manage the potential for recurrent manifestations, such as when short-term symptomatic assistance is needed to manage recurrent episodes. The primary benefit is that it is applied in addressing the overall symptom load associated with recurrent episodes, which supports general well-being during symptomatic phases.


Quick Fact: Relief for Urinary Distress

Eligibility and Restrictions for Use

Who can and cannot use Mepafuran?

The eligibility for Mepafuran (Nitrofurantoin) is strictly defined by regulatory criteria concerning patient age, organ function status, and medical history.


Contraindicated Populations

The medicine is contraindicated for patients with a known hypersensitivity to nitrofurantoin or a history of drug-associated cholestatic jaundice or hepatic dysfunction. Use is prohibited in individuals with significant impairment of renal function, specifically those with a creatinine clearance under 60 mL/minute, as well as those presenting with anuria or oliguria. Mepafuran is also contraindicated for pediatric patients under one month of age and for pregnant patients at term (38 to 42 weeks gestation).


Eligibility and Restrictions

Mepafuran is approved for use in adults and children one month of age and older. Use is not recommended for breastfeeding mothers of infants under one month old or infants with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency. Official labeling advises caution for patients with pre-existing conditions like Diabetes Mellitus or Anemia, which may enhance the occurrence of peripheral neuropathy. Older adults and individuals with debilitating diseases are subject to special consideration and cautious use due to heightened systemic risk.

What should I know about interactions with other medicines?

The following information is based on authoritative governmental regulatory documents regarding the interaction profile of Nitrofurantoin, the established medical name for the substance referred to as Mepafuran.

Interaction scope

  • Medicinal product categories with documented interactions: Uricosuric agents, Quinolone antimicrobials, Magnesium-containing antacids/supplements, Live Vaccines.
  • Specific interacting medicines (explicitly listed): Probenecid, Sulfinpyrazone, Methotrexate, Oral Cholera Vaccine (Live), Oral Typhoid Vaccine (Live).

Mechanistic basis of interactions

  • Renal Tubular Secretion Inhibition: Uricosuric agents like Probenecid and Sulfinpyrazone inhibit the renal tubular secretion of Nitrofurantoin. This reduces the concentration of the drug in the urine (potentially lowering efficacy against urinary tract infections) while increasing its concentration in the blood (potentially raising toxicity risk).
  • Reduced Absorption: Antacids containing magnesium, such as magnesium trisilicate, can significantly reduce the gastrointestinal absorption of Nitrofurantoin. A time separation of dosage is typically required.
  • Antagonism/Reduced Efficacy: Concurrent use with live bacterial vaccines (e.g., Oral Cholera Vaccine, Live) may reduce the efficacy of the vaccine. Antagonism between Nitrofurantoin and quinolone antimicrobials has been demonstrated in vitro, though its clinical significance remains uncertain.

Interaction-related restrictions

  • Contraindicated combinations: Use in patients with significant renal impairment (e.g., CrCl < 60 mL/min) is contraindicated due to the increased risk of toxicity from impaired drug excretion. The drug should also be avoided in patients with Glucose-6-Phosphate Dehydrogenase (G-6-PD) deficiency due to the risk of hemolytic anemia.

Mechanism of Action

Mepafuran (Nitrofurantoin) exerts its effect through a unique intracellular activation process, leading to a localized bactericidal effect.

Prodrug Activation by Bacterial Flavoproteins

The drug functions as an inactive prodrug until it is transported inside the bacterial cell. There, it engages with bacterial flavoproteins, primarily nitroreductases. This enzymatic interaction causes a chemical reduction, converting the inert compound into highly reactive intermediates. This step initiates the lethal mechanism and results in action largely confined to the pathogen.

Multi-Target Macromolecular Damage

Once formed, the toxic intermediates immediately inflict broad and irreversible damage. They covalently bind to and inhibit multiple critical bacterial components, including DNA, RNA, and vital metabolic enzymes (such as those involved in the Krebs cycle). This widespread assault on nucleic acids and energy pathways causes the cessation of essential life functions—replication, protein synthesis, and energy production—leading to the rapid physiological consequence of bacterial cell death.

Concentration-Dependent Specificity and Mechanism Limitations

The drug's bactericidal effect is concentration-dependent, meaning it requires achieving a high local density to overcome the instability of the reactive intermediates and facilitate the elimination of the susceptible population. This mechanism is intrinsically limited: its failure is primarily mediated by organisms that lack sufficient levels of the required nitroreductase enzymes, thereby preventing the initial activation step and allowing the pathogen to survive.

Dosage and Administration Information

Mepafuran is administered exclusively via the oral route, and specific instructions are utilized to ensure proper use.

Official Administration Guidelines

Category Official Instruction
Dosing Schedule (Adult) Acute Treatment: 50 mg to 100 mg four times a day for regular-release forms, or 100 mg twice a day for dual-release forms. Suppression: 50 mg to 100 mg once daily, typically at bedtime.
Course Duration Acute treatment typically lasts 5 to 7 days, or for at least 3 days after documentation of sterile urine. Long-term suppressive use may extend for several months.
Timing with Meals The medication must be taken with food or milk to maximize absorption and enhance gastrointestinal tolerance.
Age-Group Rules Mepafuran is not to be used in infants under 1 month of age. Pediatric doses (1 month and older) for acute infection are weight-based (5 to 7 mg/kg of body weight per 24 hours) given in four divided doses.
Preparation Oral suspension must be shaken well before measurement, and capsules/tablets should be swallowed whole.

Procedural Structure

Proper use involves adherence to a structured regimen. The dose should be consumed with food or milk and the solid form swallowed intact to maintain drug integrity. Following the prescribed dosing frequency (two or four times daily) is essential, and the full course of therapy should be completed as directed, regardless of when symptoms resolve. For a missed dose, it is generally advised to take it as soon as remembered, unless it is nearly time for the next dose, in which case the missed dose should be skipped.

Recent Clinical Evidence

Evidence for Acute Uncomplicated Urinary Tract Infections (UTIs)

Research exploring the compound's evaluation in typical lower urinary tract infections (UTIs) primarily involves short-term Randomized Controlled Trials (RCTs) and systematic reviews focused on non-pregnant adult women. Studies examined clinical endpoints, such as changes in patient-reported discomfort, and microbiological endpoints, tracking shifts in the presence of causative bacteria. Findings describe patterns related to symptomatic and microbiological outcomes, usually measured within the first 7 to 14 days. However, the overall quality of this evidence is limited, as a significant portion is historical and carries established limitations such as a high risk of bias.


Evidence for Preventing Recurrent Urinary Tract Infections (rUTIs)

For patients experiencing fluctuating or episodic infections, long-term RCTs and observational studies have explored continuous, low-dose administration. These studies focused on adult women with a history of recurrent UTIs and monitored the rate of new symptomatic episodes over many months. Studies reported that groups using the compound had patterns of lower recurrence rates compared to groups not receiving prophylactic treatment during the study period. What remains uncertain is the durability of these lower recurrence rates after the compound is stopped, and research suggests recurrence rates may revert toward baseline levels after administration ceases.


Evidence in Specific Patient Populations and Subgroups

The majority of research, including foundational RCTs, focused on adult women who did not have complicated or severe underlying medical conditions. Consequently, data for certain groups, such as pediatric populations or patients with significant renal issues, remain insufficient. Comparative evidence regarding the optimization of various administration durations or low-dose regimens for long-term use is also limited.


Evidence Gaps and Areas of Research Uncertainty

A key limitation is that evidence quality varies across studies, with older trials having methods that may not meet current scientific standards. Long-term outcomes are not well characterized outside of the prophylactic research setting. Further research is needed regarding the optimization of different low-dose regimens for long-term use in recurrent cases.

Key Studies & References

  1. Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women
  2. Urinary tract infection (recurrent): antimicrobial prescribing - NICE Guideline NG112

Frequently Asked Questions (FAQ)

Common questions about Mepafuran (FAQ)


Q: How quickly do people typically feel the effects of Mepafuran?

A: Studies and official information indicate that the medicine is rapidly absorbed and achieves high concentrations where the bacteria are located (the urinary tract). While the drug's mechanism of action involves rapid action against bacteria, clinical improvement is typically assessed over the full short course of treatment, which is usually 5 to 7 days.

Q: Can Mepafuran be taken alongside standard over-the-counter pain relievers?

A: Official documents do not typically report direct drug interactions with common over-the-counter (OTC) pain relievers. Consultation with a healthcare professional is always advisable regarding all medicines being taken, as they can provide guidance on managing minor side effects, such as headaches.

Q: Are there any specific foods or drinks that should be avoided when using Mepafuran?

A: Regulatory documents advise against concurrent use with antacids that contain magnesium, such as magnesium trisilicate, as this can significantly reduce the amount of the drug the body absorbs. Conversely, the official guidance specifies that the medicine should be taken with food or milk to help maximize its absorption and reduce the risk of stomach upset.

Q: Is it normal to feel a bit tired when starting Mepafuran?

A: Yes, according to official regulatory documents, fatigue (a feeling of extreme tiredness) and drowsiness are among the potential adverse effects reported with the use of Mepafuran.

Q: How does Mepafuran compare generally to older drugs used for the same condition?

A: Regulatory-backed clinical decision analyses support Mepafuran's therapeutic role in managing uncomplicated urinary tract infections. Its efficacy patterns are noted in relation to other agents, particularly considering resistance concerns and overall treatment patterns.

Q: Does Mepafuran have a high potential for interacting with herbal supplements?

A: The official product information suggests a discussion with a healthcare professional regarding all medicines and products, including herbal remedies and supplements. This caution exists because the interaction potential of these products has not been as extensively tested as that of prescription medicines.

Q: Can Mepafuran affect the results of standard lab blood tests?

A: Yes, official regulatory documents state that Mepafuran may interfere with laboratory testing and can cause a false positive result specifically for glucose when tested in the urine. Regulatory information indicates that patients should inform laboratory personnel that they are taking this medicine before providing a sample.

Q: What if I'm taking vitamins; will they interact with Mepafuran?

A: Official guidance suggests discussing all vitamins and supplements with a healthcare professional. Additionally, the regulatory label notes that certain existing conditions, such as a Vitamin B deficiency, may enhance the risk of serious side effects while using the drug.

Q: What is the role of Mepafuran in managing the symptoms of the condition?

A: Mepafuran's primary role is to act as an antibacterial agent (bactericidal), meaning it kills the bacteria causing the infection. By eliminating the causative pathogens in the lower urinary system, this action is the mechanism that leads to the ultimate resolution of associated symptoms.

Q: What does it mean that Mepafuran is 'metabolized' by the liver?

A: While the drug is mainly known for its activation inside bacteria, the official safety documents list the potential for serious adverse effects such as hepatic toxicity (liver damage) and chronic active hepatitis. This indicates that the liver is significantly involved in processing the drug, and liver function is an important safety consideration.

Q: Why do some people experience nausea when taking Mepafuran?

A: Nausea is classified as a common adverse event in official safety documents. This side effect is thought to be related to irritation in the stomach and digestive tract, which is why official guidance suggests taking the medication with food or milk to enhance gastrointestinal tolerance.

Q: What should be done if an adverse reaction to Mepafuran occurs?

A: For common, mild side effects, simple management (such as taking the dose with food) is often advised. Official guidance specifies that the drug should be discontinued and emergency medical attention sought if any signs of severe or serious toxicity occur (such as trouble breathing, jaundice, or severe swelling).

Q: How long does Mepafuran stay in your system after the last dose?

A: Pharmacokinetic data indicates that Mepafuran has a short elimination half-life, typically described as ranging from 0.33 to 1.7 hours. Although the concentration in the bloodstream decreases quickly, approximately 20% to 25% of the unchanged drug is usually recovered in the urine within 24 hours of the last dose.

Q: Can Mepafuran affect sleep patterns?

A: According to official documents, a potential adverse reaction is drowsiness. Any change in alertness can indirectly affect a person’s overall sleep patterns.

Q: Why is Mepafuran used for more than one condition?

A: The compound is officially indicated for two primary use scenarios described in the literature. These include the treatment of acute lower urinary tract infections and the use for long-term prophylaxis (or prevention) in patients prone to recurrent urinary tract infections.

Q: Are there any restrictions on driving or operating machinery while taking Mepafuran?

A: Official product information indicates that caution should be exercised regarding activities that require mental alertness, such as driving or operating machinery. This restriction applies if the patient experiences central nervous system side effects like dizziness or drowsiness.

Q: Does Mepafuran interact with birth control pills?

A: Official clinical guidance, including systematic reviews, generally indicates that non-rifamycin antibiotics (which includes Mepafuran) do not reduce the effectiveness of hormonal contraceptives (birth control pills). Discussing all medication combinations with a healthcare professional is recommended.

Q: Is there a generic version of Mepafuran available?

A: Yes, official product information confirms that Mepafuran's active ingredient is Nitrofurantoin. This compound is widely available and marketed under its established generic formulation name.

Q: How is Mepafuran classified by major health organizations (e.g., controlled substance)?

A: Official regulatory documents classify Mepafuran as a Prescription-only medicine and an Antibacterial agent belonging to the Nitrofuran class. It is not typically listed as a controlled substance.

Q: What should a patient do if they accidentally take more Mepafuran than usual?

A: Regulatory documents specify that in the event of taking more than the prescribed amount, emergency medical attention should be sought immediately, or a designated Poison Help line should be contacted.

Q: Why is the official guidance strict about who cannot use Mepafuran?

A: The guidance is strict because contraindications are based on preventing the risk of serious toxicity. For example, in patients with severely impaired kidney function, the drug can accumulate in the bloodstream, which is associated with an increased risk of serious side effects like peripheral neuropathy.

Q: What is the significance of the research evidence summarized for Mepafuran?

A: The body of research supports Mepafuran's therapeutic role in uncomplicated urinary tract infections. This position is supported by observed efficacy patterns and its relatively low impact on widespread antimicrobial resistance patterns.

Q: Does Mepafuran contain lactose or gluten?

A: Official labeling for some oral formulations (such as capsules) lists lactose monohydrate as an inactive ingredient. The official advice is to review the full list of inactive ingredients for the exact formulation being used.

Q: Can Mepafuran cause changes in mood or anxiety levels?

A: Official regulatory documents list mood or mental changes and mental depression as rare adverse effects that have been reported with this medication.

Q: What does the term 'contraindication' mean in relation to Mepafuran?

A: A contraindication is a core regulatory term that signifies a situation where the use of Mepafuran is strictly prohibited. This prohibition exists because, under those specific conditions (such as severe kidney impairment), the risks of taking the medicine are considered to be greater than any potential benefit.

Q: Why is alcohol consumption generally discouraged while on Mepafuran?

A: Official guidance discourages alcohol consumption primarily because it can worsen common side effects of the medicine, such as nausea and headaches. Furthermore, alcohol may also complicate recovery by potentially irritating the urinary system or causing dehydration, which can impact the infection itself.

How should Mepafuran be stored and disposed of?

To maintain the efficacy and safety of Mepafuran, proper storage is essential. Generally, the medication should be stored at room temperature, away from excessive heat and moisture. Always check the original packaging and patient information leaflet for any specific storage temperature range. Do not store Mepafuran in the bathroom, as the heat and humidity can cause the medication to degrade.

Disposal Guidelines

Item to Dispose of Recommended Method
Expired or Unused Medication Return to a local pharmacy or an authorized drug take-back program.
Original Packaging (empty) Dispose of in household trash after removing all personal information.

Never flush Mepafuran down a toilet or pour it down a sink unless specifically instructed by the accompanying drug leaflet or a healthcare professional. Improper disposal can harm the environment and compromise public health. Keep all medicines out of the sight and reach of children and pets.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mepafuran found in:

A-Z Index: